YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
How Aura Investments Stock Is Reacting To Mixed Earnings And A New Dividend Aura Investments (TASE:AURA) has drawn fresh attention after second quarter and half year results showed higher revenue alongside lower net income and earnings per…
* Aura Biosciences press release [https://seekingalpha.com/pr/20614282-aura-biosciences-reports-second-quarter-2026-financial-results-and-recent-business-highlights] (AURA [https://seekingalpha.com/symbol/AURA]): Q2 GAAP EPS of -$0.48 miss…
In trading on Friday, precious metals shares were relative leaders, up on the day by about 6.7%. Leading the group were shares of B2Gold, up about 14.6% and shares of Aura Minerals up about 12.6% on the day. Also showing relative strength…
(RTTNews) - Today's top gainers include SL Science, which was recently listed on the Nasdaq; Chemomab, gearing up for a Phase 3 trial in primary sclerosing cholangitis; Propanc, following the launch of a share repurchase program; and Tecto…
BOSTON, May 19, 2026 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ: AURA) (“Aura” or the “Company”), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today ann…
June S&P 500 E-Mini futures (ESM26) are trending up +0.46% this morning as investors shrugged off an exchange of fire between the U.S. and Iran and awaited the release of the key U.S. jobs report. The U.S. military said on Thursday that Ir…
(RTTNews) - Aura Biosciences Inc. (AURA), a clinical-stage biotechnology company, announced on Monday the pricing of its underwritten public offering of 39.59 million shares of common stock at $6 per share. Following the announcement, shar…
BOSTON, May 04, 2026 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (“Aura”) (Nasdaq: AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today announced the pricin…
Toronto Stock Exchange, TSX Venture Exchange Toronto, Ontario--(Newsfile Corp. - April 9, 2026) - TMX Group today announced its financing activity on Toronto Stock Exchange (TSX) and TSX Venture Exchange (TSXV) for March 2026. TSX welcomed…
BOSTON, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today announced that Elisabet de l…
Cadmus C. Rich, MD, MBA, as Chief Medical Officer, and Carlos Quezada-Ruiz, MD, FASRS, as Chair of the Scientific Advisory Board, bring invaluable clinical development expertise to VIS-101 ProgramThe ability to attract seasoned ophthalmolo…
Aura Minerals Inc ROAD TOWN, British Virgin Islands, Oct. 10, 2025 (GLOBE NEWSWIRE) -- Aura Minerals Inc. (NASDAQ: AUGO and B3: AURA33) (“Aura” or the “Company”) is pleased to announce Q3 2025 preliminary production results from the Compan…
ROAD TOWN, British Virgin Islands, Oct. 10, 2025 (GLOBE NEWSWIRE) -- Aura Minerals Inc. (NASDAQ: AUGO and B3: AURA33) (“Aura” or the “Company”) is pleased to announce Q3 2025 preliminary production results from the Company’s operating mine…
Aura Minerals Inc ROAD TOWN, British Virgin Islands, Sept. 23, 2025 (GLOBE NEWSWIRE) -- Aura Minerals Inc. (Nasdaq: AUGO) (B3: AURA33) (“Aura” or the “Company”) is pleased to announce that commercial production has been achieved at its Bor…
ROAD TOWN, British Virgin Islands, Sept. 23, 2025 (GLOBE NEWSWIRE) -- Aura Minerals Inc. (Nasdaq: AUGO) (B3: AURA33) (“Aura” or the “Company”) is pleased to announce that commercial production has been achieved at its Borborema gold mine (…
BOSTON, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today announced that Elisabet de…
Aura Minerals Inc ROAD TOWN, British Virgin Islands, Aug. 29, 2025 (GLOBE NEWSWIRE) -- Aura Minerals Inc. (TSX: ORA) (B3: AURA33) (NASDAQ: AUGO) (“Aura” or the “Company”) pursuant to the Comissão de Valores Mobiliários (“CVM”) Resolution N…
Continued Clinical Program Execution in the Phase 3 CoMpass Trial in Early Choroidal Melanoma and the Phase 1b/2 Trial in Non-Muscle Invasive Bladder Cancer (NMIBC) Strengthened Balance Sheet with $75 Million Equity Financing; Cash Positio…
BOSTON, May 15, 2025 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (“Aura”) (Nasdaq: AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today announced the pricin…
BOSTON, May 15, 2025 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (“Aura”) (Nasdaq: AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today announced the launch…
First Patient Enrolled in Multi-Dose Phase 1b/2 Trial of Bel-sar in Non-Muscle-Invasive Bladder Cancer (NMIBC); Initial Data at 3 Months Expected by Year-End 2025 Strengthened Leadership Team with the Appointment of Tony Gibney as Chief Fi…
BOSTON, May 01, 2025 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today announced that members of its…
We recently published a list of 10 Small Cap Stocks with Huge Upside Potential. In this article, we are going to take a look at where Aura Biosciences, Inc. (NASDAQ:AURA) stands against other small cap stocks with huge upside potential. In…
BOSTON, April 02, 2025 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today announced the appointment o…
Positive Phase 1 Trial Data in Non-Muscle Invasive Bladder Cancer (NMIBC) Presented at the 40th Annual European Association of Urology Congress; Supports Front-Line Treatment Potential Clinical Pipeline Continues to Advance with Phase 3 Co…
Aura will Participate in the Research Forum at the 40th Annual European Association of Urology Congress Aura will Host a Virtual Urologic Oncology Investor Event Featuring Key Opinion Leaders at 4:30 pm Eastern Time on March 24, 2025 BOSTO…
BOSTON, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today announced that Elisabet de l…
In this article, we will look at the 12 stocks insiders are buying now. If you want to explore similar stocks, you can also take a look at 5 Stocks Insiders are Buying Now. Investing in stocks thatinsiders are buying can sometimes lead to…
Clearside Biomedical, Inc. - Favorable Safety Profiles and Encouraging Efficacy Data Reported in Clinical Trials in the Suprachoroidal Space (SCS®) Across Multiple Therapeutic Areas using Clearside’s SCS Microinjector® - - SCS Microinjecto…
- Favorable Safety Profiles and Encouraging Efficacy Data Reported in Clinical Trials in the Suprachoroidal Space (SCS®) Across Multiple Therapeutic Areas using Clearside’s SCS Microinjector® - - SCS Microinjector® Featured in Multiple Ora…
– Villaris shareholders to receive upfront payment of $70 million, with potential for up to $1.36 billion in additional milestone payments – Pre-clinical data for auremolimab demonstrate high potency, selectivity and efficacy in vitiligo –…
Shares of Aura Biosciencs Inc. were up 11.3% in premarket trading on Thursday after the company said it received a Fast-Track designation from the Food and Drug Administration for its experimental bladder-cancer treatment. Aura is planning…
When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the stock as a bargain. Either way, this signals an opportunity to go long on the stock. Insider purchases should not be taken as the…
Good morning, trader! We’re starting the day off right with a dive into the biggest pre-market stock movers for Wednesday! Wall Street building in the morning sun representing Pre-Market Stock Movers. Source: ventdusud / Shutterstock.com W…
Gainers Bed Bath & Beyond Inc. (NASDAQ: BBBY) rose 56.4% to $26.20 in pre-market trading on the heels of three new announcements from the company outlining strategic plans to help with its turnaround. Bed Bath & Beyond increased the amount…